夏膝口服液对自发性高血压大鼠肾素、血管紧张素Ⅱ水平影响及靶器官保护作用的实验研究
|
摘要
目的：观察夏膝口服液对自发性高血压大鼠(SHR)血压、血浆肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)水平的影响，及其对心、肾等靶器官的保护作用，并初步探讨其作用机制。
方法：50只12周龄雄性SHR随机分为SHR空白组，卡托普利组，夏膝口服液高、中、低剂量组，每组10只，同时选取10只同周龄的WKY大鼠作为对照。①采用尾动脉搏动法测量实验前、实验4周、实验8周各组大鼠的血压值；②采用放射免疫法测定实验8周后各组大鼠的PRA、AngⅡ含量；③测量心／体、肾／体比值，并取左心室及肾脏组织切片，采用HE染色，在光镜下观察其组织形态变化。
结果：①各给药组大鼠血压均有不同程度下降，其中卡托普利组降压幅度最大，与夏膝口服液中、低剂量组相比有显著性差异(P＜0.05)，而与高剂量组比较则无显著差异(P＞0.05)；②PRA在夏膝口服液高、中剂量组及卡托普利组均升高，尤以卡托普利组升高显著(P＜0.05)；AngⅡ浓度，SHR空白组显著高于WKY组、卡托普利组和夏膝口服液高剂量组(P＜0.01)，而卡托普利组与夏膝口服液高剂量组之间则无明显差异(P＞0.05)；③各给药组大鼠心／体比值、肾／体比值均有不同程度下降，其中卡托普利组与夏膝口服液高剂量组最为显著(P＜0.01)；④各给药组大鼠心肌与肾脏组织经HE染色后观察，其损伤均有不同程度的减轻。
结论：①夏膝口服液可明显降低SHR的收缩压；②夏膝口服液能够降低SHR血浆中AngⅡ含量；③夏膝口服液能够降低心／体、肾／体比值，在某种程度上具有逆转SHR靶器官损害的作用。
Objective: The research was to observe the effects of Xiaxi oral liquid on the blood pressure, PRA, angiotensinⅡof spontaneously hypertensive rats, and its protection to the target organs such as heart and kidney, then to investigate the mechanisms initially. Methods: 12-week-old SHRs were assigned randomly into 5 groups: untreated, treated with captopril, treated with high dose of Xiaxi oral liquid, treated with moderate dose of Xiaxi liquid, treated with low dose of Xiaxi oral liquid, each group consists 10 rats, meanwhile 10 WKY rats the same age were selected as comparison.①Measure the pressure value of the rats before the experiment, after 4-week-treatment and after 8-week-treatment.②Detected the concentration of PRA and AngⅡof the rats after 8-week-treatment with radioimmunoassay.③Measure the ratios between the heart and the body, the kidney and the body; take the histological sections of left ventricle and kidney and color them with HE, then observe the histological changement with light microscope.
Results:①BP was deceased in every treatment group and the depressurization extent of the captopril was greatest. Comparing with the moderate and the low dose groups, there were significant differences (P＜0.05), but there were no significant differences among the high dose groups (P＞0.05).②PRA was increased in the high and the moderate dose groups and in the captoprils, especially significant in the captopril (P＜0.05). The concentration of AngⅡwas higher in the untreated groups than in the WHY, captoptil and the high dose groups (P＜0.01). And there were no significant differences between the captopril and the high dose groups (P＞0.05).③The ratios of the heart and the body, the kidney and the body were deceased to different degrees, and they were more significant in the captopril and the high dose groups (P＜0.01).④Observing the cardiac muscle and the kidney tissue after colored with HE, all of the degree of injury were deceased to different degrees.
Conclusions:①Xiaxi oral liquid can reduce the SBP of SHR significantly.②Xiaxi oral liquid can reduce the content of the plasma AngⅡ.③Xiaxi oral liquid can reduce the ratios of the heart and the body, the kidney and the body, and it has the ability to deteriorate the damage in the target organ of SHR.
方法：50只12周龄雄性SHR随机分为SHR空白组，卡托普利组，夏膝口服液高、中、低剂量组，每组10只，同时选取10只同周龄的WKY大鼠作为对照。①采用尾动脉搏动法测量实验前、实验4周、实验8周各组大鼠的血压值；②采用放射免疫法测定实验8周后各组大鼠的PRA、AngⅡ含量；③测量心／体、肾／体比值，并取左心室及肾脏组织切片，采用HE染色，在光镜下观察其组织形态变化。
结果：①各给药组大鼠血压均有不同程度下降，其中卡托普利组降压幅度最大，与夏膝口服液中、低剂量组相比有显著性差异(P＜0.05)，而与高剂量组比较则无显著差异(P＞0.05)；②PRA在夏膝口服液高、中剂量组及卡托普利组均升高，尤以卡托普利组升高显著(P＜0.05)；AngⅡ浓度，SHR空白组显著高于WKY组、卡托普利组和夏膝口服液高剂量组(P＜0.01)，而卡托普利组与夏膝口服液高剂量组之间则无明显差异(P＞0.05)；③各给药组大鼠心／体比值、肾／体比值均有不同程度下降，其中卡托普利组与夏膝口服液高剂量组最为显著(P＜0.01)；④各给药组大鼠心肌与肾脏组织经HE染色后观察，其损伤均有不同程度的减轻。
结论：①夏膝口服液可明显降低SHR的收缩压；②夏膝口服液能够降低SHR血浆中AngⅡ含量；③夏膝口服液能够降低心／体、肾／体比值，在某种程度上具有逆转SHR靶器官损害的作用。
Objective: The research was to observe the effects of Xiaxi oral liquid on the blood pressure, PRA, angiotensinⅡof spontaneously hypertensive rats, and its protection to the target organs such as heart and kidney, then to investigate the mechanisms initially. Methods: 12-week-old SHRs were assigned randomly into 5 groups: untreated, treated with captopril, treated with high dose of Xiaxi oral liquid, treated with moderate dose of Xiaxi liquid, treated with low dose of Xiaxi oral liquid, each group consists 10 rats, meanwhile 10 WKY rats the same age were selected as comparison.①Measure the pressure value of the rats before the experiment, after 4-week-treatment and after 8-week-treatment.②Detected the concentration of PRA and AngⅡof the rats after 8-week-treatment with radioimmunoassay.③Measure the ratios between the heart and the body, the kidney and the body; take the histological sections of left ventricle and kidney and color them with HE, then observe the histological changement with light microscope.
Results:①BP was deceased in every treatment group and the depressurization extent of the captopril was greatest. Comparing with the moderate and the low dose groups, there were significant differences (P＜0.05), but there were no significant differences among the high dose groups (P＞0.05).②PRA was increased in the high and the moderate dose groups and in the captoprils, especially significant in the captopril (P＜0.05). The concentration of AngⅡwas higher in the untreated groups than in the WHY, captoptil and the high dose groups (P＜0.01). And there were no significant differences between the captopril and the high dose groups (P＞0.05).③The ratios of the heart and the body, the kidney and the body were deceased to different degrees, and they were more significant in the captopril and the high dose groups (P＜0.01).④Observing the cardiac muscle and the kidney tissue after colored with HE, all of the degree of injury were deceased to different degrees.
Conclusions:①Xiaxi oral liquid can reduce the SBP of SHR significantly.②Xiaxi oral liquid can reduce the content of the plasma AngⅡ.③Xiaxi oral liquid can reduce the ratios of the heart and the body, the kidney and the body, and it has the ability to deteriorate the damage in the target organ of SHR.
引文
[1] 王爱珍，蔡治宾，吴罗杰．原发性高血压病中医辨证分型与肾素、血管紧张素Ⅱ初探[J]．中国现代医学杂志，1998，8(5)：43．
[2] 李泓，等．原发性高血压肾素、血管紧张素、醛固酮及血浆心钠素水平与辨证分型关系．中西医结合杂志1991；11(5)：271
[3] 张玲端，刘淑蕴，白智峰．原发性、肾性高血压中医症候衍变规律与RAS、ANP的关系[J]．天津中医，1993，(1)：21．
[4] 高喜源，包桂英，张雪峰，等．高血压病中医辨证心钠素，肾素血管紧张素醛固酮系统的测定[J]．实用中西医结合杂志2000，11(12)：1059．
[5] 吕圭源，李万里，沈康克，等．血灵对肾性高血压大鼠血压相关物质的影响[J]．中国中药杂志，1998，23(6)：369～371．
[6] 宋和鉴，钱士明，邢俊武．血压平滴鼻剂对自发性高血压大鼠血压血浆肾素血管紧张素的影响[J]．中医药研究，2000，16(2)：50～51．
[7] 李景新，薛冰，陈连璧．沙苑子总黄酮对高血压大鼠的降压作用及血管紧张素含量的影响[J]．中国药理学与毒理学杂志，2002，16(5)：338～339．
[8] 廖圣宝，刘光伟，张雪冰，等．滋水降火饮对肾性高血压大鼠血清细胞因子水平的影响[J]．中医药学报，2001，29(3)：60～61．
[9] 柯于鹤，屈松柏．血压平胶囊对肾血管性高血压大鼠AngⅡ及Ald的影响[J]．中国实验方剂学杂志，2003，9(5)：51～52．
[10] 袁成民．八物降压冲剂治疗原发性高血压的临床及实验研究[J]．山东中医药大学学报，1999，23(3)：37-39．
[11] 吕圭源，李万里．舒血宁对肾素．血管紧张素系统的影响[J]．中药药理与临床，1997，13(3)：37-39．
[12] 陆曙，扬笛．降防保心中药复方对肾血管性高血压大鼠肾素－血管紧张素系统的影响[J]．中国实验方剂学杂志，1999，6(5)：3．
[13] 耿秀芳，李桂芝，王守训．银杏叶总黄酮对ACE的活性的影响[J]．吉林中医药，1993，(6)：37．
[14] 钟正贤．国外医学·植物分册．1993；(8)：9
[15] 赵杰．天然药物的血管紧张素转化酶抑制活性的研究[J]．国外医学·中医中药分 册，1986，(2)：33－34．
[16] 贺师鹏，靖宇，岳保珍．甘草次酸与大鼠肝膜血管紧张素Ⅱ受体相结合[J]．中国药理学通报，1998，14(5)：19～21．
[17] 李连达．抗心肌缺血中药研究进展[J]．中国中西医结合杂志，1987，7：57．
[18] Touyz RM, Berry C.Recent advances in angiotensin Ⅱ signaling. Braz J Med Biol Res, 2002; 35 (9): 1001-1015
[19] Dimitropoulou C. Angiotensin Ⅱ relaxes microvessels via the AT(2) receptor and Ca~(2+)-activated K+(BK(Ca)) channels. Hypertension, 2001; 37(2): 301- 307
[20] Guido Grassi. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. Journal of Hypertension, 2001; 19:1713-1716
[21] K-Laflamme A, Champlain J. Interaction between the sympathetic and renin- angiotensin system. Therapie, 1998; 53(3):245-252
[22] Sasser JM, Pollock JS, Pollock DM. Renal endothelin in chronic angiotensin Ⅱ hypertension. Am J Physiol Regul Integr Comp Physiol, 2002; 283(1): R243- 248
[23] Cediel E,Vazquez-Cruz B,Navarro-Cid J,De Las Heras N, Sanz-Rosa D, Cachofeiro V, Lahera V. Role of endothelin-1 and thromboxane A_2 in renal vasoconstriction induced by angiotensin Ⅱ in diabetes and hypertension. Kidney Int Suppl, 2002; 82: 2-7.
[24] Dumont Y, D'Amours M, Lebel M, Lariviere R. Blood pressure-independent effect of angiotensin AT_1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J Hypertens, 2001; 19(8):1479-1487.
[25] Nishimura M, Milsted A, Block CH, Brosnihan KB, Ferrario CM. Tissue rennin-angiotensin systems in renal hypertension. Hypertension, 1992; 20(2): 158- 167
[26] Sadjadi J, Puttaparthi K, Welborn MB, Rogers TE, Moe O, Clagett GP, Tumage RH,Levi M, Modrall JG. Upregulation of autocrine-paracrine renin- angiotensin systems in chronic renovascular hypertension. J Vasc Surg, 2002; 36(2): 386- 392.
[27] Bryan Williams. Angiotensin Ⅱ and the Pathophysiology of Cardiovascular Remodeling. Am J Cardiol, 2001 ; 87(suppl): 10C-17C
[28] 朱吉莉，贾汝汉，王学玉．厄贝沙坦对自发性高血压大鼠肾脏的影响．中国临床医学，2002；9(4)：361-364．
[29] 李迪元，赵光胜．陆以信，等．血浆肾素活性与血浆紧张素Ⅱ浓度关系的研究．中华心血 管病杂志，1981，9(3)：192-196
[30] 公茂莲，张红叶，杨军，等．原发性高血压与血浆肾素活性及血管紧张素原遗传关系．中国循环杂志，1998，3(6)：340-342
[31] 梅仁彪，陈琳，李朝品，等．肾素-血管紧张素-醛固酮系统与矿工高血压关系初步研究．中国病理生理杂志，2001，17(12)：1175－1178
[32] 李红梅，叶季鲜，李敏，等．老年高血压者肾素系统和血管活性肤的变化．心脏杂志，2001，13(1)：46－49
[33] 李汉，卜秦莉，张静，等．原发性高血压肾素－血管紧张素-醛固酮系统与血浆心钠素水平相关性探讨．天津医药，1990，12：707－710
[34] 孙文，刘基高，汪兰珍．老年高血压患者肾素活性．血管紧张素Ⅱ水平与动态血压关系的探讨．高血压杂志，1999，3；7(1)：52－53
[35] Shimokama T, Haraoka S, Horiguchi H, et al. The Tsukuba hypertensive mouse as a model of human malignant hypertension:development of lesions and morphometric analysis[J].Virchows Arch, 1998, 432:169-175
[36] Jeunemaitre X, Rigat B, Charra A, et al. Sib pair linkage analysis of renin gene haplotypes in human essential hypertension. Hum Genet, 1992, 88:301-306
[37] Robertson JIS, Nicholls MG.The renin-angiotensin system. Gower Medical publishing, UK,1993
[38] JiH,Leung M, Zhang Y, et al. Differential structural requirements for specific binding of nonpeptide and antigonists to the AT, angiotensin receptor: identification of amino acid residues that determine binding of the antihypertensine drug Losartan [J].J Biochem, 1994, 269:16533
[39] 季乃军，应秀华，梅益斌，等．原发性高血压患者血管活性肽的测定及其临床意义．河北医学，2001，7(11)；961-963
[40] 赵光胜，李迪元，袁晓源，等．肾素-血管紧张素-醛固酮系统和高血压病关系的研究．中华心血管病杂志，1982，10(2)：113-116
[41] Harrap SB, Davidson HR, Cornor Jul, etal. The Angiotensin Converting Enzyme Gene and Predisposition to Fligh Blood Pressure[J]. Hypertension,1993, 21 (4) : 455-460
[42] Li Diyuan,Wang Geliang,Wei xianglai, et al. Study of the Relationship Gene Mutation of Renin System with Essential Hypertension [J].Joural of Shanghai Second Medical University, 1998,18(2):89-91
[43] Anderson NG, Maller JL, Tonks NK. et al. Angiotensin-Converting Enzyme polymorphism and left ventricular Hypertrophy[J].Nature, 1990, 343:651
[44] Mocdie SA, Willumsen BM, Weber MJ,et al.Angiotensinoged Gene Polymon-phism and Essential Pressure[J].Science, 1993, 260:1658
[45] Jeunemaitre X, Soubrier F, Korelevtsev YV, et al. Molecular Basis of Human Hypertension:Role of Angiotensin[J].Cell, 1992, 71(1):169, 180
[46] Soubrier F, Albence GF, Herbeth B,et al.Two putative Active Centers in Human Angiotensin Ⅰ cloning [J].ProcNatl Acad Sci USA, 1988,859(24):9386-9390.
[47] St Ollberger C, Slany J, Brainin M, et al. Angiotensin-Converting Enzyme Inhibitors and Stroke Prevention: What About the Influence of Atrial Fibrillation and Antithrombotic Therapy?[J]. Stroke, 2003, 34(11):208.
[48] 孔令星，高血压治疗中血管紧张素转换酶抑制剂(ACEI)的选用[J]．中国药事，2003，17(12)：777－779．
[49] Sugaya, H W Liu, T X Cui, et al. Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury[J]. Hypertension, 2003,42(10): 542-547.
[50] Horiuchi M. Recent Progressin AT_1 and AT_2 Receptor Research[J]. Nippon Rinsho, 2002, 60(10):1873-1880.
[51] Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation Angiotensin- Converting Enzyme 2 After M yocardial Infarction by Blockade of Angiotensin Ⅱ Receptors[J]. Hypertension, 2004,43(5):970-976.
[52] Mazzolai C, Bumier M. Comparative safety and tolerance of angiotensin Ⅱ receptor antagoists[J]. Drag Saf 1999,21:23-33.
[53] Pitt B, Reichek N, Willenbrock R, et al. Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy: The 4E-Left Ventricular Hypertrophy Study [J]. Circulation, 2003, 108(10):1831-1838.
[54] Stanton A, Jensen C, Nussberger J, et al. Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren[J]. Hypertension. 2003, 42(10):1137-1143.
[55] Dietrich FM, Alkan SS, Wood JM. et al. Monoclonal anti-bodies to human renin: properties and applications. Clin Exp Hypertens A, 1987, 9(8-9): 1259-1275.
[56] 苏予．等．抗血管紧张素Ⅱ单克隆抗体的抗高血压作用．中华心血管杂志，1991，19(3)：180－182．
[57] Reilly TM,Wong PC, Price WA, et al. Characterization of the functional antagonism and antihypertensive activity displayed by a monoclonal antibody to angiotensin Ⅱ.J Pharmacol Exp Ther, 1988,244(1):160-165.
[58] Downharn MR, Auton TR, Rosul A, et al.Evaluation of two carrier protein -angiotensin Ⅰ conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol, 2003, 56(5): 505-512.
[59] Brown MJ, Coltart J,Gunewardena K, et al. Randomised, double blind, placebo controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Loud), 2004, 24 [Epub ahead of print].
[60] Zelezna B, Velek J, Veselsky L, et al. Influence of active immunization against angiotensin AT_1 or AT_2 receptor on hypertension development in young and adult SHR.Physiol Res,1999, 48: 259-265.
[61] Wielbo D, Semia C, Gyurko R, et al. Antisense inhibition of hypertension in the spontaneously hypertensive rat.Hypertension, 1995, 25(3):314-319.
[1] Ketelhut .Hypertension, left ventricular hyperthopy and sudden death [J]. Primary Cardiol, 1991, 18:577
[2] Casale P N. Value of echocardiographic assessment of left ventricular mass in predicting cardiovascular morbid events in hypertensive men [J].Am Intern Med, 1986,105:173
[3] 张维忠，龚兰生，邱惠丽，等．动态血压与高血压性左室肥厚的关系[J]．中华心血管病杂志，1993，21(3)：138-139
[4] 王宏宇，张维忠，龚兰生，等．高血压病大动脉扩张性与左室肥厚关系的探讨[J]．中华心血管病杂志，2000，28(3)：177
[5] 张维忠．高血压与大动脉功能[J]．中华内科杂志，2000，39(5)：355
[6] Bennetl T and Cardiner SM. Recent development in endothelin research. Jhum Hyperters 1994,8:587
[7] Unger J,Chung O,Csikos T, et al, Angiotensin receptons, J Hypertens, 1996, 14(suppl5):595
[8] Radomski MW, Palmer RMJ and Moncada S. An L-anginine nitric oxide pathway present in human platelets regulates aggregation Proc Natt Acad Sci USA, 1990, 87:519
[9] 张维忠．高血压与左室肥厚[J]．临床心血管病杂志，1993，9(6)：323-325
[10] 盛勇，杨源烈．血管紧张素Ⅱ及转换酶抑制剂在高血压左室肥厚中的作用[J]．心血管病学进展，1995，16(2)：92-93
[11] 邓珏琳，黄德嘉，承永明，等．血管紧张素转换酶基因多态性与高血压左室肥厚的关系[J]．中华心血管病杂志，1999，27(2)：127
[12] 胡晓晟，吕俊陛．高血压左室肥厚与心肌间质纤维化[J]．中华心血管病杂志，1994,22(5)：387-389
[13] 李放，马晓曦，刘国仗．醛固酮致心肌间质纤维化作用的临床意义[J]．中华心血管病杂志，1994，22(6)：467-469
[14] 刘国仗，党爱民．高血压左室肥厚的发生机制、诊断和治疗[J]．中国循环杂志，1998，13(1)：89-90
[15] 刘国仗，刘力生．高血压左室肥厚与逆转[J]．中国循环杂志．1993，8(12)：707-708
[16] 柯永胜．原癌基因与心肌肥厚[J]．临床荟萃，1992，7(7)：300－301
[17] Vogt M, MH, Schwartzkopf B, et al. Pathophysiology and clinical aspects of hypertensive hypertrophy[J]. Eur Heart J,1993,14(suppl D):2-7
[18] Franz HM, Reinhard K. Left ventricular hypertrophy: a pressure independent cardiovascular risk factor[J], cardiovasc pharmacol, 1993,22(suppl 1):s7-s13
[19] 杨宁等．中医药防治高血压左室肥厚．中西医结合实用临床急救1999，6(2)：95－96
[20] 卫明等．长生降压液对中老年肾虚型高血压病及心肌肥厚影响的临床观察．中西医结合杂志，1990，10(10)：590
[21] 孙敏等．补肾填精法治疗肾虚型高血压病及心室肥厚．山东中医学院学报，1995，19(2)： 124
[22] 严灿等．心肌康对高血压病左室肥厚逆转的临床作用观察及机理探讨．中国中医药科技，1995，2(5)：17
[23] 胡乃坷等，天麻水蛭汤逆转高血压左室肥厚的临床研究．山东中医杂志，1996，15(4)：154
[24] 符德玉等．活血潜镇胶囊对自发性高血压大鼠的降压作用及其对血液流变学和心室肥厚形态学的影响．新疆中医药，1998，16(1)：39-41
[25] 周端等．活血潜阳胶囊治疗高血压病的临床与实验研究，上海中医药杂志，2000，4：22
[26] 严灿．活血祛痰法逆转高血压左心室肥厚的实验研究．中国中医基础医学杂志，1999，6(2)：95－96
[27] 李建平．活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究．中医杂志，2000，41(5)：301
[28] 刘惟莞等．水杉总黄酮对肾性高血压大鼠左室肥厚的作用．中草药，2000，31，837
[29] 唐忠志等．丹参对自发性高血压大鼠左室肥厚及心肌纤维化影响的形态学研究，中华实用医学，2002，12(4)：1－3
[30] Bidani AK, Griffin KA. Pathophysiology of hyperiensive renal damage: implications for therapy. Hypertension, 2004, 44:595-601.
[31] Beutler JJ, Koomans HA. Malignant hypertension: still a challenge. Nephrol Dial Transplant, 1997, 12:2019-2023.
[32] 汤归春，莫耘松，陈薇，等．黄芪对高血压病早期肾损害的保护作用[J]．现代中西医结合杂志，2006，15(1)：26-27
[33] 卢泓，袁丹桂．胡文英．补阳还五汤治疗高血压病无症状性蛋白尿31例[J]．实用中医药 杂志，2002，18(11)：20
[34] 刘福明，范群丽．降压益肾颗粒对原发性高血压患者尿NAG、β_2-MG、Alb的影响[J]．江苏中医药，2005，26(12)：12
[35] 唐树德等．首乌治疗早期肾脏损害血瘀型高血压患者28例．中国中西医结合杂志[J]．1994，5；302－303
[36] 朱遵贤．利水解毒法治疗高血压肾病52例．陕西中医[J]．1999，20(8)：345
[37] 张琪，朱建军．观察保元灌肠液治疗原发性高血压(EH)患者早期肾损害的疗效．南京中医药大学学报[J]．2001，17(3)；189-190
[38] 何文彬，吴颢昕，樊蓥，等．抵当口服液治疗高血压脑出血(急性期)的疗效观察[J]．辽宁中医杂志，2001，28(7)：417-418．
[39] 金许洪，潘峰，何国龙，等．地黄饮子治疗高血压脑出血术后临床观察[J]．浙江中西医结合杂志，2005，15(7)：411－412．
[40] 穆士卿，肖安平，李栓德，等．黄芪对急性脑创伤后局部脑皮质血流速度变化的影响[J]．中国中西医结合急救杂志，2004，11(1)：46．
[41] 陈富春，郭述苏．黄芪防治缺血性脑卒中的研究进展[J]．河北医学，1995，1(2)：66．
[42] 许孔煌．黄芪注射液治疗高血压脑出血临床观察[J]．中国中医急症，2005，14(3)：237-238．
[43] 黄培新等．毛冬青甲素对高血压性大鼠脑内血肿及脑微血管超微结构的影响．中国中医急症，1997，6(3)：127．
[1] 任继学，任继学经验集，人民卫生出版社，2000，133-134．
[2] 汉·许慎．说文解字，北京：中华书局影印本：15．
[3] 张永言，杜仲陵，向熹，等．古汉语字典，成都：四川人民出版社，1986，第1版：144．
[4] 清·徐大椿．徐大椿医书全集，北京：人民卫生出版社，1988，第1版：185．
[5] 清·沈括．梦溪笔谈，上海：上海古籍出版社，1987，第1版：480．
[6] 王永炎．关于提高脑血管疾病疗效难点的思考[J]．中国中西医结合杂志，1997，17(4)：195．
[7] 邓铁涛．高血压病辨证论治的体会[J]．新中医，1980，(2)：10．
[8] Liao D F. JenniferL. Duff. Guenter Daum, et al. Angiotensin Ⅱ Stim-uiates MAP Kinase Activity in Vascular Smooth Muscle Cells: Role of Roaf. Cir Res, 1996; 79: 1007-1014.
[9] 秦旭平，廖端芳，李元建．血管平滑肌细胞增殖及其调控[J]．中国动脉硬化杂志，2001；9(5)：450-454．
[10] 叶任高主编．全国高等医药院校教材．内科学，第五版：259．
[11] Jin M. Wilhelm MJ. Lang RE, et al. Endogenous tissue renin angiotensin system. Am J Med, 1998;84:28.
[12] Ohkubo H, Nakayama K, Tanaka T, et al. Tissue distribution of angiotensin mRNA and structural analysis of its heterogeneity. J Biol Chem, 1986; 216:319.
[13] 杨和平，邢德智，汤健，等．血管内皮素和血管紧张素Ⅱ释放的相互关系[J]．中国病理生理杂志，1992；8：610．
[14] Nakamurea M, Jackson EK, Inagami T, et al. Betaadreno receptor mediated release of angiotensin Ⅱ from mesenteric arteries. Am J Physiol, 1986; 250:H144.
[15] 孙双丹，许慧，吴建明，等．内皮素和血管紧张素Ⅱ对大鼠血管平滑肌细胞分裂的促进作用[J]．基础医学与临床，1993；13：55．
[16] Geisterfer AAJ, Peach MJ, Owens GK,et al. Angiotensin Ⅱ induces hypertrophy, not hyperplasia of cultural rat aortic smooth muscle cells, Cir Res, 1988,62:749.
[17] Asaad MM, Antonaccio MJ. Vascular wall renin in spontaneously hypertensive rats. Hypertension,1982;4:478.
[18] 阳斌、高广道，卢兴．心肌局部肾素—血管紧张素系统在大鼠容量负荷性心肌肥大中 的作用[J]．中国病理生理杂志，1993；9：116．
[19] Kai T. Kino H. Ishikawa K, Role of the renin-angiotension system in cardiac hypertrophy and renal glomerular sclerosis in transgenc hypertensive mice carrying both human renin and angiotensinogen genes[J]. Hypertens Res, 1998; 21(1): 39.
[20] 谢燕，顾振伦．氯沙坦和卡托普利联合应用对高血压大鼠肾脏的保护作用[J]．中国药学杂志，2002；37(8)：585－588．
[2] 李泓，等．原发性高血压肾素、血管紧张素、醛固酮及血浆心钠素水平与辨证分型关系．中西医结合杂志1991；11(5)：271
[3] 张玲端，刘淑蕴，白智峰．原发性、肾性高血压中医症候衍变规律与RAS、ANP的关系[J]．天津中医，1993，(1)：21．
[4] 高喜源，包桂英，张雪峰，等．高血压病中医辨证心钠素，肾素血管紧张素醛固酮系统的测定[J]．实用中西医结合杂志2000，11(12)：1059．
[5] 吕圭源，李万里，沈康克，等．血灵对肾性高血压大鼠血压相关物质的影响[J]．中国中药杂志，1998，23(6)：369～371．
[6] 宋和鉴，钱士明，邢俊武．血压平滴鼻剂对自发性高血压大鼠血压血浆肾素血管紧张素的影响[J]．中医药研究，2000，16(2)：50～51．
[7] 李景新，薛冰，陈连璧．沙苑子总黄酮对高血压大鼠的降压作用及血管紧张素含量的影响[J]．中国药理学与毒理学杂志，2002，16(5)：338～339．
[8] 廖圣宝，刘光伟，张雪冰，等．滋水降火饮对肾性高血压大鼠血清细胞因子水平的影响[J]．中医药学报，2001，29(3)：60～61．
[9] 柯于鹤，屈松柏．血压平胶囊对肾血管性高血压大鼠AngⅡ及Ald的影响[J]．中国实验方剂学杂志，2003，9(5)：51～52．
[10] 袁成民．八物降压冲剂治疗原发性高血压的临床及实验研究[J]．山东中医药大学学报，1999，23(3)：37-39．
[11] 吕圭源，李万里．舒血宁对肾素．血管紧张素系统的影响[J]．中药药理与临床，1997，13(3)：37-39．
[12] 陆曙，扬笛．降防保心中药复方对肾血管性高血压大鼠肾素－血管紧张素系统的影响[J]．中国实验方剂学杂志，1999，6(5)：3．
[13] 耿秀芳，李桂芝，王守训．银杏叶总黄酮对ACE的活性的影响[J]．吉林中医药，1993，(6)：37．
[14] 钟正贤．国外医学·植物分册．1993；(8)：9
[15] 赵杰．天然药物的血管紧张素转化酶抑制活性的研究[J]．国外医学·中医中药分 册，1986，(2)：33－34．
[16] 贺师鹏，靖宇，岳保珍．甘草次酸与大鼠肝膜血管紧张素Ⅱ受体相结合[J]．中国药理学通报，1998，14(5)：19～21．
[17] 李连达．抗心肌缺血中药研究进展[J]．中国中西医结合杂志，1987，7：57．
[18] Touyz RM, Berry C.Recent advances in angiotensin Ⅱ signaling. Braz J Med Biol Res, 2002; 35 (9): 1001-1015
[19] Dimitropoulou C. Angiotensin Ⅱ relaxes microvessels via the AT(2) receptor and Ca~(2+)-activated K+(BK(Ca)) channels. Hypertension, 2001; 37(2): 301- 307
[20] Guido Grassi. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. Journal of Hypertension, 2001; 19:1713-1716
[21] K-Laflamme A, Champlain J. Interaction between the sympathetic and renin- angiotensin system. Therapie, 1998; 53(3):245-252
[22] Sasser JM, Pollock JS, Pollock DM. Renal endothelin in chronic angiotensin Ⅱ hypertension. Am J Physiol Regul Integr Comp Physiol, 2002; 283(1): R243- 248
[23] Cediel E,Vazquez-Cruz B,Navarro-Cid J,De Las Heras N, Sanz-Rosa D, Cachofeiro V, Lahera V. Role of endothelin-1 and thromboxane A_2 in renal vasoconstriction induced by angiotensin Ⅱ in diabetes and hypertension. Kidney Int Suppl, 2002; 82: 2-7.
[24] Dumont Y, D'Amours M, Lebel M, Lariviere R. Blood pressure-independent effect of angiotensin AT_1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J Hypertens, 2001; 19(8):1479-1487.
[25] Nishimura M, Milsted A, Block CH, Brosnihan KB, Ferrario CM. Tissue rennin-angiotensin systems in renal hypertension. Hypertension, 1992; 20(2): 158- 167
[26] Sadjadi J, Puttaparthi K, Welborn MB, Rogers TE, Moe O, Clagett GP, Tumage RH,Levi M, Modrall JG. Upregulation of autocrine-paracrine renin- angiotensin systems in chronic renovascular hypertension. J Vasc Surg, 2002; 36(2): 386- 392.
[27] Bryan Williams. Angiotensin Ⅱ and the Pathophysiology of Cardiovascular Remodeling. Am J Cardiol, 2001 ; 87(suppl): 10C-17C
[28] 朱吉莉，贾汝汉，王学玉．厄贝沙坦对自发性高血压大鼠肾脏的影响．中国临床医学，2002；9(4)：361-364．
[29] 李迪元，赵光胜．陆以信，等．血浆肾素活性与血浆紧张素Ⅱ浓度关系的研究．中华心血 管病杂志，1981，9(3)：192-196
[30] 公茂莲，张红叶，杨军，等．原发性高血压与血浆肾素活性及血管紧张素原遗传关系．中国循环杂志，1998，3(6)：340-342
[31] 梅仁彪，陈琳，李朝品，等．肾素-血管紧张素-醛固酮系统与矿工高血压关系初步研究．中国病理生理杂志，2001，17(12)：1175－1178
[32] 李红梅，叶季鲜，李敏，等．老年高血压者肾素系统和血管活性肤的变化．心脏杂志，2001，13(1)：46－49
[33] 李汉，卜秦莉，张静，等．原发性高血压肾素－血管紧张素-醛固酮系统与血浆心钠素水平相关性探讨．天津医药，1990，12：707－710
[34] 孙文，刘基高，汪兰珍．老年高血压患者肾素活性．血管紧张素Ⅱ水平与动态血压关系的探讨．高血压杂志，1999，3；7(1)：52－53
[35] Shimokama T, Haraoka S, Horiguchi H, et al. The Tsukuba hypertensive mouse as a model of human malignant hypertension:development of lesions and morphometric analysis[J].Virchows Arch, 1998, 432:169-175
[36] Jeunemaitre X, Rigat B, Charra A, et al. Sib pair linkage analysis of renin gene haplotypes in human essential hypertension. Hum Genet, 1992, 88:301-306
[37] Robertson JIS, Nicholls MG.The renin-angiotensin system. Gower Medical publishing, UK,1993
[38] JiH,Leung M, Zhang Y, et al. Differential structural requirements for specific binding of nonpeptide and antigonists to the AT, angiotensin receptor: identification of amino acid residues that determine binding of the antihypertensine drug Losartan [J].J Biochem, 1994, 269:16533
[39] 季乃军，应秀华，梅益斌，等．原发性高血压患者血管活性肽的测定及其临床意义．河北医学，2001，7(11)；961-963
[40] 赵光胜，李迪元，袁晓源，等．肾素-血管紧张素-醛固酮系统和高血压病关系的研究．中华心血管病杂志，1982，10(2)：113-116
[41] Harrap SB, Davidson HR, Cornor Jul, etal. The Angiotensin Converting Enzyme Gene and Predisposition to Fligh Blood Pressure[J]. Hypertension,1993, 21 (4) : 455-460
[42] Li Diyuan,Wang Geliang,Wei xianglai, et al. Study of the Relationship Gene Mutation of Renin System with Essential Hypertension [J].Joural of Shanghai Second Medical University, 1998,18(2):89-91
[43] Anderson NG, Maller JL, Tonks NK. et al. Angiotensin-Converting Enzyme polymorphism and left ventricular Hypertrophy[J].Nature, 1990, 343:651
[44] Mocdie SA, Willumsen BM, Weber MJ,et al.Angiotensinoged Gene Polymon-phism and Essential Pressure[J].Science, 1993, 260:1658
[45] Jeunemaitre X, Soubrier F, Korelevtsev YV, et al. Molecular Basis of Human Hypertension:Role of Angiotensin[J].Cell, 1992, 71(1):169, 180
[46] Soubrier F, Albence GF, Herbeth B,et al.Two putative Active Centers in Human Angiotensin Ⅰ cloning [J].ProcNatl Acad Sci USA, 1988,859(24):9386-9390.
[47] St Ollberger C, Slany J, Brainin M, et al. Angiotensin-Converting Enzyme Inhibitors and Stroke Prevention: What About the Influence of Atrial Fibrillation and Antithrombotic Therapy?[J]. Stroke, 2003, 34(11):208.
[48] 孔令星，高血压治疗中血管紧张素转换酶抑制剂(ACEI)的选用[J]．中国药事，2003，17(12)：777－779．
[49] Sugaya, H W Liu, T X Cui, et al. Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury[J]. Hypertension, 2003,42(10): 542-547.
[50] Horiuchi M. Recent Progressin AT_1 and AT_2 Receptor Research[J]. Nippon Rinsho, 2002, 60(10):1873-1880.
[51] Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation Angiotensin- Converting Enzyme 2 After M yocardial Infarction by Blockade of Angiotensin Ⅱ Receptors[J]. Hypertension, 2004,43(5):970-976.
[52] Mazzolai C, Bumier M. Comparative safety and tolerance of angiotensin Ⅱ receptor antagoists[J]. Drag Saf 1999,21:23-33.
[53] Pitt B, Reichek N, Willenbrock R, et al. Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy: The 4E-Left Ventricular Hypertrophy Study [J]. Circulation, 2003, 108(10):1831-1838.
[54] Stanton A, Jensen C, Nussberger J, et al. Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren[J]. Hypertension. 2003, 42(10):1137-1143.
[55] Dietrich FM, Alkan SS, Wood JM. et al. Monoclonal anti-bodies to human renin: properties and applications. Clin Exp Hypertens A, 1987, 9(8-9): 1259-1275.
[56] 苏予．等．抗血管紧张素Ⅱ单克隆抗体的抗高血压作用．中华心血管杂志，1991，19(3)：180－182．
[57] Reilly TM,Wong PC, Price WA, et al. Characterization of the functional antagonism and antihypertensive activity displayed by a monoclonal antibody to angiotensin Ⅱ.J Pharmacol Exp Ther, 1988,244(1):160-165.
[58] Downharn MR, Auton TR, Rosul A, et al.Evaluation of two carrier protein -angiotensin Ⅰ conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol, 2003, 56(5): 505-512.
[59] Brown MJ, Coltart J,Gunewardena K, et al. Randomised, double blind, placebo controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Loud), 2004, 24 [Epub ahead of print].
[60] Zelezna B, Velek J, Veselsky L, et al. Influence of active immunization against angiotensin AT_1 or AT_2 receptor on hypertension development in young and adult SHR.Physiol Res,1999, 48: 259-265.
[61] Wielbo D, Semia C, Gyurko R, et al. Antisense inhibition of hypertension in the spontaneously hypertensive rat.Hypertension, 1995, 25(3):314-319.
[1] Ketelhut .Hypertension, left ventricular hyperthopy and sudden death [J]. Primary Cardiol, 1991, 18:577
[2] Casale P N. Value of echocardiographic assessment of left ventricular mass in predicting cardiovascular morbid events in hypertensive men [J].Am Intern Med, 1986,105:173
[3] 张维忠，龚兰生，邱惠丽，等．动态血压与高血压性左室肥厚的关系[J]．中华心血管病杂志，1993，21(3)：138-139
[4] 王宏宇，张维忠，龚兰生，等．高血压病大动脉扩张性与左室肥厚关系的探讨[J]．中华心血管病杂志，2000，28(3)：177
[5] 张维忠．高血压与大动脉功能[J]．中华内科杂志，2000，39(5)：355
[6] Bennetl T and Cardiner SM. Recent development in endothelin research. Jhum Hyperters 1994,8:587
[7] Unger J,Chung O,Csikos T, et al, Angiotensin receptons, J Hypertens, 1996, 14(suppl5):595
[8] Radomski MW, Palmer RMJ and Moncada S. An L-anginine nitric oxide pathway present in human platelets regulates aggregation Proc Natt Acad Sci USA, 1990, 87:519
[9] 张维忠．高血压与左室肥厚[J]．临床心血管病杂志，1993，9(6)：323-325
[10] 盛勇，杨源烈．血管紧张素Ⅱ及转换酶抑制剂在高血压左室肥厚中的作用[J]．心血管病学进展，1995，16(2)：92-93
[11] 邓珏琳，黄德嘉，承永明，等．血管紧张素转换酶基因多态性与高血压左室肥厚的关系[J]．中华心血管病杂志，1999，27(2)：127
[12] 胡晓晟，吕俊陛．高血压左室肥厚与心肌间质纤维化[J]．中华心血管病杂志，1994,22(5)：387-389
[13] 李放，马晓曦，刘国仗．醛固酮致心肌间质纤维化作用的临床意义[J]．中华心血管病杂志，1994，22(6)：467-469
[14] 刘国仗，党爱民．高血压左室肥厚的发生机制、诊断和治疗[J]．中国循环杂志，1998，13(1)：89-90
[15] 刘国仗，刘力生．高血压左室肥厚与逆转[J]．中国循环杂志．1993，8(12)：707-708
[16] 柯永胜．原癌基因与心肌肥厚[J]．临床荟萃，1992，7(7)：300－301
[17] Vogt M, MH, Schwartzkopf B, et al. Pathophysiology and clinical aspects of hypertensive hypertrophy[J]. Eur Heart J,1993,14(suppl D):2-7
[18] Franz HM, Reinhard K. Left ventricular hypertrophy: a pressure independent cardiovascular risk factor[J], cardiovasc pharmacol, 1993,22(suppl 1):s7-s13
[19] 杨宁等．中医药防治高血压左室肥厚．中西医结合实用临床急救1999，6(2)：95－96
[20] 卫明等．长生降压液对中老年肾虚型高血压病及心肌肥厚影响的临床观察．中西医结合杂志，1990，10(10)：590
[21] 孙敏等．补肾填精法治疗肾虚型高血压病及心室肥厚．山东中医学院学报，1995，19(2)： 124
[22] 严灿等．心肌康对高血压病左室肥厚逆转的临床作用观察及机理探讨．中国中医药科技，1995，2(5)：17
[23] 胡乃坷等，天麻水蛭汤逆转高血压左室肥厚的临床研究．山东中医杂志，1996，15(4)：154
[24] 符德玉等．活血潜镇胶囊对自发性高血压大鼠的降压作用及其对血液流变学和心室肥厚形态学的影响．新疆中医药，1998，16(1)：39-41
[25] 周端等．活血潜阳胶囊治疗高血压病的临床与实验研究，上海中医药杂志，2000，4：22
[26] 严灿．活血祛痰法逆转高血压左心室肥厚的实验研究．中国中医基础医学杂志，1999，6(2)：95－96
[27] 李建平．活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究．中医杂志，2000，41(5)：301
[28] 刘惟莞等．水杉总黄酮对肾性高血压大鼠左室肥厚的作用．中草药，2000，31，837
[29] 唐忠志等．丹参对自发性高血压大鼠左室肥厚及心肌纤维化影响的形态学研究，中华实用医学，2002，12(4)：1－3
[30] Bidani AK, Griffin KA. Pathophysiology of hyperiensive renal damage: implications for therapy. Hypertension, 2004, 44:595-601.
[31] Beutler JJ, Koomans HA. Malignant hypertension: still a challenge. Nephrol Dial Transplant, 1997, 12:2019-2023.
[32] 汤归春，莫耘松，陈薇，等．黄芪对高血压病早期肾损害的保护作用[J]．现代中西医结合杂志，2006，15(1)：26-27
[33] 卢泓，袁丹桂．胡文英．补阳还五汤治疗高血压病无症状性蛋白尿31例[J]．实用中医药 杂志，2002，18(11)：20
[34] 刘福明，范群丽．降压益肾颗粒对原发性高血压患者尿NAG、β_2-MG、Alb的影响[J]．江苏中医药，2005，26(12)：12
[35] 唐树德等．首乌治疗早期肾脏损害血瘀型高血压患者28例．中国中西医结合杂志[J]．1994，5；302－303
[36] 朱遵贤．利水解毒法治疗高血压肾病52例．陕西中医[J]．1999，20(8)：345
[37] 张琪，朱建军．观察保元灌肠液治疗原发性高血压(EH)患者早期肾损害的疗效．南京中医药大学学报[J]．2001，17(3)；189-190
[38] 何文彬，吴颢昕，樊蓥，等．抵当口服液治疗高血压脑出血(急性期)的疗效观察[J]．辽宁中医杂志，2001，28(7)：417-418．
[39] 金许洪，潘峰，何国龙，等．地黄饮子治疗高血压脑出血术后临床观察[J]．浙江中西医结合杂志，2005，15(7)：411－412．
[40] 穆士卿，肖安平，李栓德，等．黄芪对急性脑创伤后局部脑皮质血流速度变化的影响[J]．中国中西医结合急救杂志，2004，11(1)：46．
[41] 陈富春，郭述苏．黄芪防治缺血性脑卒中的研究进展[J]．河北医学，1995，1(2)：66．
[42] 许孔煌．黄芪注射液治疗高血压脑出血临床观察[J]．中国中医急症，2005，14(3)：237-238．
[43] 黄培新等．毛冬青甲素对高血压性大鼠脑内血肿及脑微血管超微结构的影响．中国中医急症，1997，6(3)：127．
[1] 任继学，任继学经验集，人民卫生出版社，2000，133-134．
[2] 汉·许慎．说文解字，北京：中华书局影印本：15．
[3] 张永言，杜仲陵，向熹，等．古汉语字典，成都：四川人民出版社，1986，第1版：144．
[4] 清·徐大椿．徐大椿医书全集，北京：人民卫生出版社，1988，第1版：185．
[5] 清·沈括．梦溪笔谈，上海：上海古籍出版社，1987，第1版：480．
[6] 王永炎．关于提高脑血管疾病疗效难点的思考[J]．中国中西医结合杂志，1997，17(4)：195．
[7] 邓铁涛．高血压病辨证论治的体会[J]．新中医，1980，(2)：10．
[8] Liao D F. JenniferL. Duff. Guenter Daum, et al. Angiotensin Ⅱ Stim-uiates MAP Kinase Activity in Vascular Smooth Muscle Cells: Role of Roaf. Cir Res, 1996; 79: 1007-1014.
[9] 秦旭平，廖端芳，李元建．血管平滑肌细胞增殖及其调控[J]．中国动脉硬化杂志，2001；9(5)：450-454．
[10] 叶任高主编．全国高等医药院校教材．内科学，第五版：259．
[11] Jin M. Wilhelm MJ. Lang RE, et al. Endogenous tissue renin angiotensin system. Am J Med, 1998;84:28.
[12] Ohkubo H, Nakayama K, Tanaka T, et al. Tissue distribution of angiotensin mRNA and structural analysis of its heterogeneity. J Biol Chem, 1986; 216:319.
[13] 杨和平，邢德智，汤健，等．血管内皮素和血管紧张素Ⅱ释放的相互关系[J]．中国病理生理杂志，1992；8：610．
[14] Nakamurea M, Jackson EK, Inagami T, et al. Betaadreno receptor mediated release of angiotensin Ⅱ from mesenteric arteries. Am J Physiol, 1986; 250:H144.
[15] 孙双丹，许慧，吴建明，等．内皮素和血管紧张素Ⅱ对大鼠血管平滑肌细胞分裂的促进作用[J]．基础医学与临床，1993；13：55．
[16] Geisterfer AAJ, Peach MJ, Owens GK,et al. Angiotensin Ⅱ induces hypertrophy, not hyperplasia of cultural rat aortic smooth muscle cells, Cir Res, 1988,62:749.
[17] Asaad MM, Antonaccio MJ. Vascular wall renin in spontaneously hypertensive rats. Hypertension,1982;4:478.
[18] 阳斌、高广道，卢兴．心肌局部肾素—血管紧张素系统在大鼠容量负荷性心肌肥大中 的作用[J]．中国病理生理杂志，1993；9：116．
[19] Kai T. Kino H. Ishikawa K, Role of the renin-angiotension system in cardiac hypertrophy and renal glomerular sclerosis in transgenc hypertensive mice carrying both human renin and angiotensinogen genes[J]. Hypertens Res, 1998; 21(1): 39.
[20] 谢燕，顾振伦．氯沙坦和卡托普利联合应用对高血压大鼠肾脏的保护作用[J]．中国药学杂志，2002；37(8)：585－588．